ROSEN urges Telix Pharmaceuticals Ltd. (TLX) investors to act before January 9, 2026 deadline

Rosen Law Firm — a global investor‑rights law firm — has issued a reminder for anyone who purchased securities of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) between February 21, 2025 and August 28, 2025 (the “Class Period”) to secure legal counsel before the firm‑set lead‑plaintiff deadline on January 9, 2026. If you fall within that group of investors, you may be eligible for compensation through a contingency‑fee arrangement — meaning no upfront fees or out‑of‑pocket costs. To participate, Rosen recommends submitting the firm’s online form or contacting attorney Phillip Kim via phone or email before the deadline. According to the class‑action complaint, Telix allegedly made materially misleading statements (or withheld material information) concerning: The progress of its prostate‑cancer therapeutic candidates, The quality and reliability of its supply‑chain and business partners, And, overall, inflated its business prospects and operations. When these details came to light, investors reportedly suffered financial losses — prompting Rosen Law Firm to take legal action on behalf of affected shareholders. #Telix #ClassAction #RosenLawFirm #InvestorAlert #SlimScan #GrowthStocks #CANSLIM